Takhzyro denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for takhzyro are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Takhzyro for Medical Necessity — and How to Appeal

A medical-necessity denial for Takhzyro (lanadelumab) for HAE prophylaxis usually means UHC's reviewer concluded that the submitted documentation did not establish that your attack burden, prior treatment history, or clinical severity meets the specific criteria in the plan's coverage policy. This is almost always a documentation gap, not an irreversible clinical verdict.

This is highly appealable when your prescriber assembles a complete, criteria-mapped submission that directly answers every requirement in UHC's policy.

## Federal Appeal Rights

• ACA §2719 / ERISA §503 provide the right to internal appeal and, if denied, external review by an independent organization.
• Internal appeal deadline: 180 days from the denial notice.
• External review window: approximately 4 months after final internal denial.
• Expedited review (72-hour decision) is appropriate given that uncontrolled HAE attacks — particularly laryngeal — carry mortality risk.

## Appeal Timeline

1. Request the full denial letter, including the specific policy criteria UHC applied. 2. Obtain UHC's current Takhzyro or HAE prophylaxis coverage policy from the provider portal. 3. Submit a written internal appeal with a complete documentation package. 4. UHC must respond within 30 days standard or 72 hours expedited. 5. If denied, escalate to external IRO immediately.

## Documentation to Gather

• Diagnosis confirmation: Genetic testing or laboratory confirmation of HAE type (C1-inhibitor deficiency, functional deficiency, or FXII-related), with report date.
• Attack history: Comprehensive log of HAE attacks in the prior 12 months — frequency, anatomical location, severity, emergency-department or hospital visits.
• Prior treatment history: Dates, agents used, doses, and documented outcomes or reasons for discontinuation for each prior acute and prophylactic HAE therapy tried.
• Clinical severity documentation: Chart notes from your HAE specialist or immunologist documenting disease burden, quality-of-life impact, and risk of life-threatening attacks.
• Prescriber medical-necessity letter: Detailed letter from your treating physician explaining why Takhzyro is medically necessary given your specific attack pattern, prior treatment experience, and clinical risk — referencing applicable guidelines from the relevant guideline organization (e.g., applicable US HAE or allergy/immunology society guidance) without quoting specific numbers.
• Failed or inadequate prior prophylaxis: If you previously tried another long-term prophylactic and it was insufficient, provide chart documentation of that outcome.

## Criteria-Mapping Structure

Copy each requirement from UHC's published Takhzyro coverage policy and answer it with a specific chart fact:

| Policy Criterion | Documented Evidence | |---|---| | HAE diagnosis confirmed by [method] | [Lab/genetic report with date] | | Minimum attack frequency | [Attack log summary] | | Prior prophylactic therapy tried | [Agent, start/end date, outcome] | | Prescriber specialty requirement | [Prescriber credentials/specialty] |

Verify you are meeting each criterion against the FDA-approved prescribing information at DailyMed and UHC's own published policy — both documents should be cited in your appeal letter.